UBS Oncology Impact Fund L.P.
CIK 1691428 · last filed 2023-06-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$133.48M
Companies
5
Total Filings
33
Lifetime Open-Market Net
-$38.62M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| iTeos Therapeutics, Inc. (ITOS) Delisted | 10%+ Owner | 4,515,075 | $10.15 | $45.83M | -$91.36M | 6 | 2022-01-06 |
| CGEM | 10%+ Owner | 7,657,817 | $17.43 | $133.48M | -$1.48M | 2 | 2021-09-16 |
| Harpoon Therapeutics, Inc. (HARP) Delisted | 10%+ Owner | 1,037,659 | $23.01 | $23.88M | $5.15M | 3 | 2021-05-17 |
| Oncorus, Inc. (ONCR) Delisted | 10%+ Owner | 1,525,348 | $0.12 | $183.9K | $9.07M | 1 | 2020-10-08 |
| TCR2 THERAPEUTICS INC. (TCRR) Delisted | 10%+ Owner | 3,370,982 | $1.48 | $4.99M | $40.00M | 1 | 2019-02-21 |
Recent Filings · Page 2 of 4
33 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-12-22 | HOWL | Notice (144) | −107,463 | -$73.8K | EDGAR |
| 2025-12-10 | HOWL | Notice (144) | −73,195 | -$73.9K | EDGAR |
| 2025-12-03 | HOWL | Notice (144) | −107,463 | -$92.4K | EDGAR |
| 2025-11-24 | HOWL | Notice (144) | −107,463 | -$93.8K | EDGAR |
| 2025-11-17 | HOWL | Notice (144) | −107,463 | -$98.7K | EDGAR |
| 2025-11-10 | HOWL | Notice (144) | −107,463 | -$123.6K | EDGAR |
| 2025-11-04 | HOWL | Notice (144) | −107,463 | -$140.8K | EDGAR |
| 2025-10-30 | HOWL | Notice (144) | −107,463 | -$167.6K | EDGAR |
| 2025-10-27 | HOWL | Notice (144) | −107,463 | -$190.2K | EDGAR |
| 2023-06-05 | — | Other (J) | −10,112,946 | $0 |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.